Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person’s daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases.
The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.
Key Targets in the Dementia Pipeline Drugs Market
Some of the targets in the dementia pipeline drugs market are Microtubule Associated Protein Tau, Acetylcholinesterase, Alpha Synuclein, Amyloid Beta A4 Protein, Glutamate Ionotropic Receptor NMDA Type Subunit, Progranulin, 5-Hydroxytryptamine Receptor 2A, TAR DNA Binding Protein 43, 1 Phosphatidylinositol 3 Phosphate 5 Kinase, and Cannabinoid Receptor 2.
Dementia pipeline drugs market, by targets
For more target insights, download a free report sample
Mechanisms of Action in the Dementia Pipeline Drugs Market
Some of the mechanisms of action in the dementia pipeline drugs market are Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Progranulin Activator, 5-Hydroxytryptamine Receptor 2A Antagonist, TAR DNA Binding Protein 43 Inhibitor, 1 Phosphatidylinositol 3 Phosphate 5 Kinase Inhibitor, Cannabinoid Receptor 2 Agonist, and Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist.
Dementia pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
Routes of Administration in the Dementia Pipeline Drugs Market
The routes of administration in the dementia pipeline drugs market are oral, intravenous, subcutaneous, nasal, parenteral, transdermal, intramuscular, intracerebral, intracisternal, and intrathecal.
Dementia pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
Molecule Types in the Dementia Pipeline Drugs Market
The molecule types in the dementia pipeline drugs market are small molecule, monoclonal antibody, gene therapy, cell therapy, synthetic peptide, biologic, peptide, conjugate vaccine, recombinant protein, and subunit vaccine.
Dementia pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Key Dementia Pipeline Drugs Market Companies
Some of the key companies in the dementia pipeline drugs market are ADEL Inc, Eisai Co Ltd, AcuraStem Inc, Alkermes Plc, Coya Therapeutics Inc, Merck & Co Inc, P2D Inc, Whan In Pharm Co Ltd, AFFiRiS AG, and Alector Inc.
Dementia pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
Targets | Microtubule Associated Protein Tau, Acetylcholinesterase, Alpha Synuclein, Amyloid Beta A4 Protein, Glutamate Ionotropic Receptor NMDA Type Subunit, Progranulin, 5-Hydroxytryptamine Receptor 2A, TAR DNA Binding Protein 43, 1 Phosphatidylinositol 3 Phosphate 5 Kinase, and Cannabinoid Receptor 2 |
Mechanisms of Action | Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Progranulin Activator, 5-Hydroxytryptamine Receptor 2A Antagonist, TAR DNA Binding Protein 43 Inhibitor, 1 Phosphatidylinositol 3 Phosphate 5 Kinase Inhibitor, Cannabinoid Receptor 2 Agonist, and Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist |
Routes of Administration | Oral, Intravenous, Subcutaneous, Nasal, Parenteral, Transdermal, Intramuscular, Intracerebral, Intracisternal, and Intrathecal |
Molecule Types | Small Molecule, Monoclonal Antibody, Gene Therapy, Cell Therapy, Synthetic Peptide, Biologic, Peptide, Conjugate Vaccine, Recombinant Protein, and Subunit Vaccine |
Key Companies | ADEL Inc, Eisai Co Ltd, AcuraStem Inc, Alkermes Plc, Coya Therapeutics Inc, Merck & Co Inc, P2D Inc, Whan In Pharm Co Ltd, AFFiRiS AG, and Alector Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
- Reviews of pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in the Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- Evaluation of Dementia (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Dementia (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AbbVie Inc
Acadia Pharmaceuticals Inc
Actinogen Medical Ltd
AcuraStem Inc
Adamed Pharma SA
ADEL Inc
AFFiRiS AG
AgeneBio Inc
AIBIOS Co Ltd
Alector Inc
Alkermes Plc
AlphaCognition Inc
Alterity Therapeutics Ltd
Alzamend Neuro Inc
Amarantus Bioscience Holdings Inc
Anavex Life Sciences Corp
Anhorn Medicines Co Ltd
Annovis Bio Inc
Aphios Corp
Applied Genetic Technologies Corp
Aprinoia Therapeutics Inc
Aptinyx Inc
AriBio
Arkuda Therapeutics Inc
Arvinas Inc
Asahi Kasei Pharma Corp
Asceneuron SA
AskAt Inc
Astrogen Ltd
Athira Pharma Inc
AULBIO Co Ltd
Aurum Biosciences Ltd
Autifony Therapeutics Ltd
Avanir Pharmaceuticals Inc
AviadoBio Ltd
Avineuro Pharmaceuticals Inc
Avrion Therapeutics AG
Axon Neuroscience SE
Axsome Therapeutics Inc
Bioasis Technologies Inc
Biogen Inc
Biom Therapeutics LLC
Biorchestra Co Ltd
BioXcel Therapeutics Inc
CAMP4 Therapeutics Corp
Cellivery Therapeutics Inc
Cellular Biomedicine Group Ltd
Cennerv Pharma (S) Pte Ltd
Cerevel Therapeutics Holdings Inc
ChunLab Inc
Cogentis Therapeutics Inc
Cognition Therapeutics Inc
Cortice Biosciences Inc
Coya Therapeutics Inc
CSPC NBP Pharmaceutical Co Ltd
CuraSen Therapeutics Inc
Cyclerion Therapeutics Inc
Dadang & BIO Co Ltd
Daewoong Pharmaceutical Co Ltd
Denali Therapeutics Inc
DiaMedica Therapeutics Inc
Dongkook Pharmaceutical Co Ltd
Dr. August Wolff GmbH & Co KG Arzneimittel
Echo Pharmaceuticals BV
EIP Pharma LLC
Eisai Co Ltd
Eli Lilly and Co
ENCEFA
Ensol Biosciences Inc
Enterin Inc
EVER Neuro Pharma GmbH
Expansion Therapeutics Inc
Galimedix Therapeutics Ltd
Generian Pharmaceuticals Inc
Gismo Therapeutics Inc
GraySpace Therapeutics Inc
Guangzhou Magpie Pharmaceutical Co Ltd
HanAll Biopharma Co Ltd
Hemostemix Inc
Herophilus
HLB Pharmaceutical Co Ltd
Hyundai Pharma Co Ltd
IGC Pharma LLC
Immungenetics AG
ImStar Therapeutics Inc
Inhibikase Therapeutics Inc
Intra-Cellular Therapies Inc
IntraBio Ltd
Inventage Lab Inc
Ionis Pharmaceuticals Inc
IRLAB Therapeutics AB
Jazz Pharmaceuticals Plc
Johnson & Johnson
KeifeRx LLC
Kogenix Therapeutics Inc
Korea Pharma Co Ltd
Kuano Ltd
Kwang Dong Pharmaceutical Co Ltd
Lachesis Biosciences Ltd
Locanabio Inc
Luye Pharma Group Ltd
MediPost Co Ltd
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
Metro International Biotech LLC
MGC Pharmaceuticals Ltd
MThera Pharma Co Ltd
MYND Life Sciences Inc
Neuramedy Co Ltd
Neurimmune Holding AG
Neurokine Therapeutics
NeuroScientific Biopharmaceuticals Ltd
NeuroTau Inc
Neuvivo Inc
NLS Pharmaceutics AG
Novartis AG
Novo Nordisk AS
Oligomerix inc
Orchard Therapeutics Plc
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
P2D Inc
Pacific Northwest Biotechnology LLC
Palisades Therapeutics
Park of Active Molecules
Passage Bio Inc
Plico Biotech Inc
Prediction BioSciences SAS
ProMIS Neurosciences Inc
Prothena Corp Plc
Psy Therapeutics Inc
PurMinds NeuroPharma Inc
QurAlis Corporation
Reata Pharmaceuticals Inc
Reborna Biosciences Inc
Resverlogix Corp
Reven Holdings Inc
Rubedo Life Sciences Inc
Sage Therapeutics Inc
Samus Therapeutics Inc
Shaperon Inc
Sinfonia Biotherapeutics Inc
Sio Gene Therapies Inc
SK Chemicals Co Ltd
SOLA Biosciences LLC
Stealth BioTherapeutics Corp
Stemedica Cell Technologies Inc
Sun Pharma Advanced Research Company Ltd
Suven Life Sciences Ltd
SyneuRx International Corp
T3D Therapeutics Inc
Targeted Pharmaceuticals LLC
TauRx Therapeutics Ltd
Teitur Trophics ApS
Theranexus SAS
Time Therapeutics Inc
Towa Pharmaceutical Co Ltd
Tranquis Therapeutics Inc
Transposon Therapeutics Inc
UCB SA
UniQure NV
Unity Biotechnology Inc
Vanqua Bio Inc
Vaxxinity Inc
Verge Genomics Inc
Voyager Therapeutics Inc
Wave Life Sciences Ltd
Whan In Pharm Co Ltd
Yumanity Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Dementia pipeline drugs market?
Some of the targets of the dementia pipeline drugs market are Microtubule Associated Protein Tau, Acetylcholinesterase, Alpha Synuclein, Amyloid Beta A4 Protein, Glutamate Ionotropic Receptor NMDA Type Subunit, Progranulin, 5-Hydroxytryptamine Receptor 2A, TAR DNA Binding Protein 43, 1 Phosphatidylinositol 3 Phosphate 5 Kinase, and Cannabinoid Receptor 2.
-
What are the mechanisms of action of the Dementia pipeline drugs market?
Some of the mechanisms of action of the dementia pipeline drugs market are Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Progranulin Activator, 5-Hydroxytryptamine Receptor 2A Antagonist, TAR DNA Binding Protein 43 Inhibitor, 1 Phosphatidylinositol 3 Phosphate 5 Kinase Inhibitor, Cannabinoid Receptor 2 Agonist, and Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist.
-
What are the routes of administration in the Dementia pipeline drugs market?
The routes of administration in the dementia pipeline drugs market are oral, intravenous, subcutaneous, nasal, parenteral, transdermal, intramuscular, intracerebral, intracisternal, and intrathecal.
-
What are the molecule types in the Dementia pipeline drugs market?
The molecule types in the dementia pipeline drugs market are small molecule, monoclonal antibody, gene therapy, cell therapy, synthetic peptide, biologic, peptide, conjugate vaccine, recombinant protein, and subunit vaccine.
-
Which are the key companies in the Dementia pipeline drugs market?
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.